The Human Genome Sequencing Center at Baylor College of Medicine increases its fleet of Roche Genome Sequencer FLX systems to ten instruments
With ten Genome Sequencer FLXs, the Human Genome Sequencing Center will be in a unique position to apply 454 Life Sciences technologies to problems ranging from the deciphering of new genomes to the analysis of mutations associated with human diseases.
"These instruments previously proved their capabilities in the arena of whole genome sequencing," said Richard Gibbs, professor and director of the Human Genome Sequencing Center at Baylor College of Medicine, and a former member of the 454 Life Sciences Scientific Advisory Board until March 2007.
To better understand genetic basis for disease - including cancer, heart disease, and asthma - genomic information from large numbers of individuals need to be analysed in a rapid and cost-effective manner.
Rapid DNA sequencing technologies allow researchers to identify all genetic changes when comparing healthy individuals to those with disease.
"Baylor's investment in the Genome Sequencer FLX as a production system is a testament to 454 Sequencing's status as the next-generation sequencing standard", explained Christopher Mcleod, president and CEO of 454 Life Sciences.
"Baylor chose the GS FLX from a field of sequencing competitors because of its proven performance and its scalability to significantly greater throughput and read length".
These efforts using the Genome Sequencer FLX are further enhanced by a collaboration with the Human Genome Sequencing Center at Baylor College of Medicine and another Roche company, Roche NimbleGen.
Preliminary work from the collaboration was reported in Nature Methods this week, and uses microarrays to capture up to 6500 human gene parts, or 'exons,' for sequence analysis, reducing the dependence on large-scale polymerase chain reaction.
"With this combination of 454 and NimbleGen methods, we have an unprecedented ability to detect changes across the human genome," said Gibbs.
The new Genome Sequencer FLX systems will also be applied to the analysis of bacterial genomes in a National Institutes of Health supported effort to analyse 'metagenomes' - collections of bacteria that live in human hosts both normally and in infectious disease.
"The GS FLX system has been remarkably successful - not only for human medical resequencing - but also for microbial genome sequencing.
"Expanding our sequencing capabilities with the additional systems figures prominently in our plans for the Human Microbiome Project," said George Weinstock, co-director and leader of microbial genomics programmes for the Human Genome Sequencing Center.
In addition to the purchase agreement, the centre and Roche also expanded their prior collaboration.
The centre will obtain early access to next generation updates to the Genome Sequencer FLX.
Planned improvements will include an increase in sequence read length beyond 400 base pairs and throughput in excess of one billion bases per day.
These system improvements, based on enhancements to the reagents and software, utilise the same hardware configuration that is currently available and purchased as part of this agreement.
